Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2022 Filed Dec 13, 2022 20:12 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027387 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,413 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 1,542 | $87.97 | $135,649.74 |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,636 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,101 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 486 | $87.97 | $42,753.42 |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,109 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,924 Underlying: Common Stock · 318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 149 | $87.97 | $13,107.53 |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,502 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:15 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027390 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,140 Underlying: Common Stock · 5,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 2,268 | $82.60 | $187,336.80 |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,556 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 5,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:49 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025413 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,513 Underlying: Common Stock · 1,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:49 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 851 | $82.60 | $70,292.60 |
DisclosureSEC source: 0001127602-22-025413 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,668 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:49 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 1,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025413 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,416 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,694 Underlying: Common Stock · 6,416 shares Expires 2031-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
SaleCommon Stock | 6,416 | $83.50 | $535,736.00 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:20 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 6,416 | $63.91 | $410,046.56 |
DisclosureSEC source: 0001127602-22-025292 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 16,255 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,255 shares Expires 2027-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
SaleCommon Stock | 16,255 | $79.25 | $1,288,208.75 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:57 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 16,255 | $72.70 | $1,181,738.50 |
DisclosureSEC source: 0001127602-22-024778 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 22:49 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 35.2119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023127 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077.4234 Underlying: Common Stock · 35.2119 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,242 Underlying: Common Stock · 318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 148 | $65.28 | $9,661.44 |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:03 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022289 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,239 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 481 | $65.28 | $31,399.68 |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,725 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,713 Underlying: Common Stock · 3,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 1,528 | $65.28 | $99,747.84 |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,878 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:09 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022294 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,425 Underlying: Common Stock · 1,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:09 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 476 | $65.28 | $31,073.28 |
DisclosureSEC source: 0001127602-22-022294 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,607 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:09 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 1,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022294 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:08 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022292 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,298 Underlying: Common Stock · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:08 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 458 | $65.28 | $29,898.24 |
DisclosureSEC source: 0001127602-22-022292 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,903 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:08 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022292 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,560 Underlying: Common Stock · 2,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 1,066 | $63.14 | $67,307.24 |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,163 Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 21:26 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 2,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020842 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 24, 2022 Filed Jul 26, 2022 16:31 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019775 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,288 Underlying: Common Stock · 7,505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| July 24, 2022 Filed Jul 26, 2022 16:31 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 3,206 | $60.80 | $194,924.80 |
DisclosureSEC source: 0001127602-22-019775 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,371 Read SEC document |
| July 24, 2022 Filed Jul 26, 2022 16:31 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 7,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-019775 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 23:18 UTC |
Lofton Kevin EDirector
|
GrantPhantom Stock · Derivative | 35.1339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018309 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,042.2115 Underlying: Common Stock · 35.1339 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,278 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 485 | $60.74 | $29,458.90 |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,014 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 1,539 | $60.74 | $93,478.86 |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,105 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.